NW Natural Holdings Reports Fourth Quarter and Full Year 2022 Results
Initiated 2023 earnings guidance and reaffirmed long-term EPS growth rate target PORTLAND, Ore.–(BUSINESS WIRE)–Northwest Natural…
Initiated 2023 earnings guidance and reaffirmed long-term EPS growth rate target PORTLAND, Ore.–(BUSINESS WIRE)–Northwest Natural…
Press release – No. 1 / 2023 Zealand Pharma to Host Conference Call on March…
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland…
TOKYO and SEOUL, Feb 24, 2023 – (JCN Newswire) – Olympus Corporation (Olympus), a global…
TOKYO, Feb 24, 2023 – (JCN Newswire) – Fujitsu and Tokai National Higher Education and…
HONG KONG, Feb 24, 2023 – (ACN Newswire) – Organised by the Hong Kong Trade…
PETALING JAYA, Malaysia, Feb 24, 2023 – (ACN Newswire) – Malaysian Genomics Resource Centre Berhad,…
ALIVE Active Shooter Survival, an in-person active shooter training provider based in California, is now…
Victoria, British Columbia–(Newsfile Corp. – February 23, 2023) – WeCommerce Holdings Ltd. (TSXV: WE) (“WeCommerce”…
Athonet acquisition strengthens HPE’s private networking capabilities to help enterprise customers accelerate 5G deployments and…
CLINUVEL Financial Performance CLINUVEL Group financial performance for the half year ended 30 December, since…
NEW YORK–(BUSINESS WIRE)–Today, Macquarie Global Infrastructure Total Return Fund Inc. (the “Fund”), a New York…
PHILADELPHIA–(BUSINESS WIRE)–Today, Delaware Ivy High Income Opportunities Fund (the “Fund”), a New York Stock Exchange-listed…
PHILADELPHIA–(BUSINESS WIRE)–Today, Delaware Enhanced Global Dividend and Income Fund (the “Fund”), a New York Stock…
PHILADELPHIA–(BUSINESS WIRE)–Today, Delaware Investments Dividend and Income Fund, Inc. (the “Fund”), a New York Stock…
Represents 7th Consecutive Year of 20% or More Constant Currency Revenue Growth ACTON, Mass.–(BUSINESS WIRE)–Please…
Combined company will be focused on advancing Enliven’s clinical-stage pipeline of precision oncology programs Shares…
– Initiated enrollment in Phase 1B clinical trial of SL-172154 in combination with mirvetuximab soravtansine…
— Company expects to announce data for Factor VIII expression in non-human primates in 2023…
FREMONT, CA, Feb. 23, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:…